(-0.32%) 5 019.48 points
(0.28%) 37 923 points
(-0.42%) 15 592 points
(-3.21%) $79.30
(-2.71%) $1.937
(0.69%) $2 318.70
(0.61%) $26.82
(1.60%) $963.40
(-0.08%) $0.936
(-0.14%) $11.08
(0.07%) $0.801
(-0.05%) $93.40
0.42% $ 13.14
Live Chart Being Loaded With Signals
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe...
Stats | |
---|---|
Dzisiejszy wolumen | 17 818.00 |
Średni wolumen | 99 631.00 |
Kapitalizacja rynkowa | 359.25M |
Następna data zysków | ( $0 ) 2024-06-03 |
Last Dividend | $0.300 ( 2023-11-21 ) |
Next Dividend | $0 ( N/A ) |
P/E | 16.63 |
ATR14 | $0.0160 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-30 | Saba Capital Management, L.p. | Buy | 16 573 | Common Stock |
2024-04-26 | Saba Capital Management, L.p. | Buy | 120 304 | Common Stock |
2024-04-25 | Saba Capital Management, L.p. | Buy | 97 574 | Common Stock |
2024-04-24 | Saba Capital Management, L.p. | Buy | 20 529 | Common Stock |
2024-04-23 | Saba Capital Management, L.p. | Buy | 48 203 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 58 transactions |
Buy: 554 423 | Sell: 55 759 |
Wolumen Korelacja
Tekla Life Sciences Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
FPI | 0.888 |
TSN | 0.883 |
ASH | 0.878 |
DHX | 0.878 |
AMRC | 0.874 |
DVN | 0.873 |
CWT | 0.871 |
PDS | 0.868 |
CVX | 0.867 |
EBR-B | 0.864 |
10 Najbardziej negatywne korelacje | |
---|---|
VCRA | -0.862 |
AMAM | -0.861 |
COR | -0.86 |
SCX | -0.856 |
IOT | -0.853 |
NGL | -0.845 |
FPAC-UN | -0.845 |
MOG-B | -0.842 |
TNK | -0.835 |
TK | -0.831 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Tekla Life Sciences Korelacja - Waluta/Towar
Tekla Life Sciences Finanse
Annual | 2023 |
Przychody: | $23.52M |
Zysk brutto: | $18.28M (77.71 %) |
EPS: | $0.830 |
FY | 2023 |
Przychody: | $23.52M |
Zysk brutto: | $18.28M (77.71 %) |
EPS: | $0.830 |
FY | 2022 |
Przychody: | $-103.25M |
Zysk brutto: | $-108.80M (105.37 %) |
EPS: | $-4.07 |
FY | 2021 |
Przychody: | $65.69M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $2.78 |
Financial Reports:
No articles found.
Tekla Life Sciences Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.310 (N/A) |
$0.310 (N/A) |
$0.330 (N/A) |
$0.320 (N/A) |
$0.320 (N/A) |
$0.300 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $1.640 | 1996-11-14 |
Last Dividend | $0.300 | 2023-11-21 |
Next Dividend | $0 | N/A |
Payout Date | 2024-01-10 | |
Next Payout Date | N/A | |
# dividends | 99 | -- |
Total Paid Out | $43.17 | -- |
Avg. Dividend % Per Year | 5.54% | -- |
Score | 5.04 | -- |
Div. Sustainability Score | 1.232 | |
Div.Growth Potential Score | 1.007 | |
Div. Directional Score | 1.119 | -- |
Year | Amount | Yield |
---|---|---|
1996 | $1.640 | 10.80% |
1997 | $0.740 | 5.38% |
1998 | $0.360 | 2.76% |
1999 | $1.110 | 9.06% |
2000 | $4.16 | 20.50% |
2001 | $3.14 | 14.90% |
2002 | $2.18 | 10.20% |
2003 | $1.240 | 10.10% |
2004 | $1.365 | 8.62% |
2005 | $2.06 | 13.00% |
2006 | $1.240 | 7.90% |
2007 | $1.170 | 8.74% |
2008 | $1.100 | 8.33% |
2009 | $0.420 | 4.59% |
2010 | $0.520 | 5.46% |
2011 | $1.010 | 9.29% |
2012 | $1.160 | 10.00% |
2013 | $1.390 | 9.19% |
2014 | $1.770 | 8.72% |
2015 | $2.80 | 11.20% |
2016 | $2.07 | 8.99% |
2017 | $1.620 | 9.38% |
2018 | $1.620 | 8.18% |
2019 | $1.400 | 9.03% |
2020 | $1.560 | 8.98% |
2021 | $1.690 | 8.71% |
2022 | $1.360 | 7.05% |
2023 | $1.270 | 8.87% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.568 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0556 | 1.200 | 8.15 | 9.78 | [0 - 0.3] |
returnOnEquityTTM | 0.0813 | 1.500 | -0.207 | -0.311 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0000000 | 2.00 | 0.0000000 | 0.0000000 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0000000 | 2.00 | 0.0000000 | 0.0000000 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.867 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.568 | 1.000 | 0.649 | 0.649 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.0978 | 0.800 | -2.68 | -2.14 | [0.5 - 2] |
Total Score | 1.232 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 15.67 | 1.000 | 8.52 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0813 | 2.50 | -0.133 | -0.311 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0000000 | 2.00 | 0.0000000 | 0.0000000 | [0 - 30] |
dividendYielPercentageTTM | 10.17 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0000000 | 2.00 | 0.0000000 | 0.0000000 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0619 | 1.500 | -3.75 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0000000 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | 1.007 |
Tekla Life Sciences
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej